companiesCompany
Galapagos
Galapagos is a biotech pursuing decentralised, seven-day vein-to-vein CAR-T manufacturing at hospital sites; it restructured its cell-therapy business in 2025.
Uses Lonza's Cocoon at partner hospitals for GLPG5101 (CD19) and GLPG5201; announced in 2025 a separation of the cell-therapy unit and a strategic review. Verify current corporate status before citing.